뇌질환의 혁신, 뉴로벤티(NeuroVenti)

ABOUT

NeuroVenti contributes to creating a society where we work together.

  • 2015
    • 07Company founded
  • 2016
    • 04Secured first CDRO (drug screening) project
  • 2017
    • 06Selected for the Industry-University-Research Cooperation Technology Development Project by the Ministry of SMEs and Startups (MSS)
    • 06Selected for the Tech Incubator Program for Startup Korea (TIPS)
  • 2018
    • 08Selected as a resident startup at Seoul Bio Hub
  • 2020
    • 01Filed patent application for NV01-A02
    • 07Closed Series A funding round
    • 09Selected for the AI Voucher Support Project by the National IT Industry Promotion Agency (NIPA)
  • 2021
    • 05Completed efficacy studies for NV01-A02
    • 06Completed efficacy studies for NV01-A03
    • 08NV01-A02 selected as drug candidate for Autism Spectrum Disorder (ASD)
    • 08Relocated headquarters to Gangnam-gu
    • 11Secured CDRO (depression drug efficacy) project
    • 11Recognized as an Outstanding Health and Medical Technology Company by the Korea Health Industry Development Institute (KHIDI)
  • 2022
    • 05Registered patent for NV01-A03 (Korea)
    • 07Received IND approval for NV01-E01 exploratory clinical trial
    • 07Received the Korea Excellent Patent Award from Hankook Ilbo and the Korea Institute of Patent Information (KIPI)
    • 07Secured CDRO (ADHD drug efficacy) project
    • 10NV01-A02 granted US FDA Orphan Drug Designation (ODD) as the first treatment for Fragile X Syndrome (FXS)
    • 12Selected for the Non-Face-to-Face Service Voucher Project
  • 2023
    • 04Registered patent for NV01-A02 (Korea)
    • 07Registered patent for NV01-062 (Korea)
    • 12Registered patent for NV01-A03 (Japan)
    • 12CNS non-clinical CDRO business exceeded annual sales target
  • 2024
    • 05Registered patent for NV01-A02 (Japan)
    • 07Received IND approval for NV01-A02 Phase 2 clinical trial
    • 08Registered patent for NV01-A02 (China)
    • 11Closed Series B funding round
  • 2025
    • 03Selected for the Investment Attraction Support Project by the Korea Health Industry Development Institute (KHIDI)
    • 03Enrolled first subject (FPFV: First Patient, First Visit) in NV01-A02 Phase 2 clinical trial
    • 05Selected as a "Baby Unicorn" company by the Ministry of SMEs and Startups (MSS)
    • 08Registered patent for NV01-A03 (US)
    • 08Selected for the Bio-Health Industry Technology Assessment–Commercialization Linkage Support Project
    • 09Registered patent for NV01-A02 (Europe)
    • 09Relocated NeuroVenti headquarters to Bongeunsa-ro, Gangnam-gu
    • 10Registered patent for NV01-062 (Japan)
    • 11Enrolled last subject (LPI) in NV01-A02 Phase 2 clinical trial
    • 11Received EPO decision to grant patent for NV01-A03 (Europe)